retatrutide phase 3 trials results for have been released, and the data are generating a lot of discussion in obesity medicine. TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and followed participants for Retatrutide Phase 3: TRIUMPH Program
Description
Analysts estimate that demand for GLP-1 injection devices could reach well over one billion units per year, with production concentrated across a relatively small number of high-volume programmes
Conflicts of interest The authors have no conflicts of interest to disclose
Semaglutide for chronic weight management has been evaluated in clinical trials extending up to 68 weeks, with patients losing on the order of 15 percent of initial body weight , and semaglutide has been associated with up to roughly 16 percent weight loss over placebo
Nutrients 11 (3), 585 (2019)
